Tenderwize
Retour à la recherche

Open house drug discount agreements for active substance Interferon beta-1b, ATC L03AB08

AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse·Eisenberg, Germany·Deadline Mar 31, 2027 · 163 days left·Open·Supplies
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Interferon beta-1b, ATC L03AB08

60/100

Score d'opportunité

PromisingLow complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

60 / 100

Complexité

30 / 100

Facteurs de risque

Open house contracts can be replaced by exclusive contracts at any time, leading to automatic termination.

Initial submission deadline (April 30, 2025) is only 19 days after notice publication (April 11, 2025).

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Informations clés

Pouvoir adjudicateur
AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse
Pays
Allemagne
CPV
33600000 - Pharmaceutical products
Date limite
Mar 31, 2027

Aperçu

Strong opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until May 2027
  • Conclusion of non-exclusive discount agreements for Interferon beta-1b under open-house model
  • Contracts available to all interested pharmaceutical companies
Afficher le résumé complet

Non-exclusive discount agreement ('Rabattvertrag') for the active substance Interferon beta-1b (ATC L03AB08) under an open-house model. All interested pharmaceutical companies meeting eligibility can join. Contracts run up to 24 months from June 1, 2025. Initial submission deadline for first contracts: April 30, 2025. No estimated value provided. The notice explicitly states it is not a public procurement under EU law; published for transparency only.

Risques

Open house contracts can be replaced by exclusive contracts at any time, leading to automatic termination.

Initial submission deadline (April 30, 2025) is only 19 days after notice publication (April 11, 2025).

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Proof of marketability via Lauer-Taxe listing or AMIce database extract

Eligibility

  • Only authorized and marketable medicines in Germany are eligible

Administrative

  • Submission of signed contract documents by specified deadlines

Les exigences peuvent être incomplètes.

Acheteur

Localisation

Eisenberg, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE271900642

Activité

Health

Lots (1)

LOT-0001

Open house drug discount agreements for active substance Interferon beta-1b, ATC L03AB08

Conclusion of non-exclusive discount agreements for Interferon beta-1b under open-house model. All pharmaceutical companies can join under uniform conditions. Contracts are non-exclusive and may be replaced by exclusive agreements later. Maximum contract duration 24 months.

SuppliesEU fundedElectronic submission

Localisation

Eisenberg, Germany

Durée

May 2025 - May 2027

Catégorie

Pharmaceutical products

Détails de la procédure

Date de publication
10 Apr 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
235668-2025

Documents (1)

Appels d'offres similaires